Meeting
2023 ASCO Genitourinary Cancers Symposium
Assessment of treatment patterns and real-world outcomes following changes in the treatment paradigm for locally advanced/metastatic urothelial carcinoma (la/mUC) in the US.
Authors
Melissa Kirker
Pfizer, New York, NY
Melissa Kirker , Anup Abraham , Anna Vlahiotis , Abhijeet Bhanegaonkar , Darrin Benjumea , Chai Kim , Haiyan Sun , Mairead Kearney , Sanjana Chandrasekar , Benjamin Li , Sheena Thakkar , Helen H Moon
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Quality of Care/Quality Improvement and Real-World Evidence
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 468)
DOI
10.1200/JCO.2023.41.6_suppl.468
Abstract #
468
Poster Bd #
H9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Genitourinary Cancers Symposium
Disease management and frontline treatment of locally advanced or metastatic urothelial (la/mUC) carcinoma: The U.S. physician PARADIGM study.
First Author: Shilpa Gupta
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world (rw) treatment patterns, sequencing, and outcomes in patients (pts) with locally advanced or metastatic urothelial carcinoma (la/mUC) receiving avelumab first-line maintenance (1LM) in the US.
First Author: Helen H. Moon
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns and sequencing in patients with locally advanced or metastatic urothelial cancer (la/mUC) in the US.
First Author: Mairead Kearney
Poster
2018 Genitourinary Cancers Symposium
Overall survival and treatment patterns among real-world patients with locally advanced or metastatic urothelial carcinoma treated with first-line therapy.
First Author: Jason C Simeone